isabelobrien, Author at European Medical Journal - Page 50 of 66

Pursuing a pathway of preventative medicine

A world without illness or disease sounds like a far-off fantasy, but some players in the pharmaceutical industry are investigating how to transform this vision into a reality.

Pharma in China

As China enters the year of the tiger – a symbol of strength and bravery – GOLD journeys to this powerhouse nation to explore how it has become the second largest pharmaceutical market in the world

Renewed focus on patient adherence

Patient adherence is the focus of a new project launched by the Innovative Medicines Initiative (IMI) and led by Pfizer.

Risks to supply chain stability

In the wake of COVID-19, GOLD investigates the potential impact of unpredictable events on the industry’s complex distribution network to understand its resilience and vulnerability.

Cancer treatment collaboration announced

Queen’s University Belfast has entered into a collaboration and licensing agreement with Ipsen to research, develop, manufacture and commercialise FLIP inhibitors.

Ripples of change in R&D

How can pharma companies improve inclusivity across their R&D cycles?

The biotech boom: fad or forever?

Biotechs have stood as agile hubs for drug discovery, but now they are being coveted by investors.

Standing out in a crowd of digital content

The amount of digital content being created for healthcare professionals has grown exponentially. Medical affairs teams must find a way to cut through the noise with their communications

A cautionary tale of digital transformation

As the pharmaceutical industry embraces digital transformation, new technologies have the potential to sink or swim. How can the industry ensure it’s backing the most effective innovations and not getting stuck in dead ends?

The future of pharmaceutical sales

The COVID-19 pandemic has reshaped pharmaceutical sales, moving from face-to-face to predominantly digital interactions. How can sales reps adapt to multichannel approaches and enhance performance amidst this shift in sales training and team dynamics?